Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06260722 · ClinicalTrials.gov registry record · Phase 3
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
- 20
- Study locations
NCT06260722 is a Phase 3 study of Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,250 participants, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06260722, a Phase 3 study of Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Retatrutide
Study Locations (20)
California
- Neighborhood Healthcare Institute of Health - Escondido
- Long Beach Research Institute - Long Beach
- Valley Clinical Trials, Inc. - Northridge
- Rancho Cucamonga Clinical Research - Rancho Cucamonga
Florida
- Arrow Clinical Trials - Daytona Beach
- New Age Medical Research Corporation - Miami
- South Broward Research - Miramar
- Clinical Research of Central Florida - Winter Haven
Georgia
- Herman Clinical Research - Suwanee
- North Georgia Clinical Research - Woodstock
Massachusetts
- Brigham and Women's Hospital Diabetes Program - Boston
- NECCR PrimaCare Research - Fall River
Alabama
- University of Alabama - Department of Nutrition Sciences - Birmingham
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Hawaii
- Pacific Diabetes & Endocrine Center - Honolulu
Idaho
- Rocky Mountain Clinical Research - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06260722
The ClinicalTrials.gov registry entry for NCT06260722 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (72% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Semaglutide is the first listed.
NCT06260722 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06260722 about?
NCT06260722 is a clinical study titled "Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)". The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and ...
What is the current status of trial NCT06260722?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2024-02-21. Estimated completion is 2027-01.
What conditions does trial NCT06260722 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT06260722?
The interventions under investigation include: Semaglutide (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT06260722?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06260722 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
-
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.